BV100 not checked

BioVersys AG

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
11 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“300 mg BV100 nfused over 2 hours every 12 hours (q12h).Treatment for 7 days up to 14 days if clinically indicated.”In the company’s words, NCT07326540 on ClinicalTrials.gov
Tested for
Hospital Acquired Bacterial Pneumonia (HABP) (2 trials), Ventilator Associated Bacterial Pneumonia (VABP) (2 trials), Colistin Resistanrt ABC, Acinetobacter Baumannii-calcoaceticus Complex, Blood Stream Infection, Meningitis, Bacterial, Ventriculitis, Infectious
Main trialPhase 3
“This is a two-part study, with Part A being the randomized, controlled portion of the study in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) suspected or confirmed to be due to carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC). Part B is the single-group portion of the study and includes patients with HABP or VABP with CRABC infections that are resistant to or have failed colistin/polymyxin B treatment.”In the company’s words, NCT07326540 on ClinicalTrials.gov
Other names
Rifabutin for Infusion

Other drugs for Hospital Acquired Bacterial Pneumonia (HABP)

All 7 drugs for Hospital Acquired Bacterial Pneumonia (HABP)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Dec 2027 Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
Phase 2Not yet recruiting Mar 2028 Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
Phase 1Recruiting 30 Sep 2026 A Single Centre, Open-label, 2-period Fixed-sequence, Phase I Clinical Study to Evaluate the Effect of BV100 on the Pharmacokinetics of Polymyxin B in Healthy Volunteers
Phase 2Completed 1 Nov 2024 PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB
Phase 1Completed 12 Dec 2021 Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Male Subjects
Phase 1Completed 8 Apr 2022 Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Healthy Male Subjects
Phase 1Completed 30 May 2022 Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
Phase 1Completed 31 Jul 2023 A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants
Phase 1Completed 30 Sep 2023 To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100
Phase 1Completed 30 Jul 2024 A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment
Phase 1Completed 30 Oct 2024 Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow BV100

Following is part of Solo: you see every change to BV100 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in